Bern Pollock uses close to 10 products from different manufacturers to manage his urostomy after bladder cancer. He explains why Medicare bidding concerns him.
|Articles|June 6, 2013
PD-1 Inhibitors are a game changer
Author(s)Guest
Advertisement
Michael Wong, melanoma oncologist and CURE advisory board member, explains how recent studies are targeting the PD-1 pathway and describes why there is so much excitement surrounding this new class of immunotherapy.
Advertisement
Related to this article
A metastatic breast cancer survivor shares how exercise gave her a sense of control while emphasizing why it should never be used to blame people with cancer.
A long-term metastatic ovarian cancer survivor explains how a trifecta of hope, purpose and grace has shaped her life through years of treatment.
Six-year PERSEUS results show 81% of newly diagnosed, transplant-eligible myeloma patients had no cancer progression, with many stopping Darzalex.
A phase 3 trial found that adding Imdelltra to Imfinzi maintenance improved survival in extensive-stage small cell lung cancer, while another drug's application was pulled. Here's what patients should know.
Living with metastatic breast cancer can make Pinktober feel complicated. One patient reflects on awareness, research, loss and remembering the people behind the pink.
A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.
Learn how nipple-sparing mastectomy, including endoscopic approaches, may help preserve appearance, reduce scarring and support breast cancer recovery.
Advertisement
Advertisement
Trending on CURE
1
Phase 3 Trial Shows Adding Imdelltra to First-Line Treatment Helps Patients With SCLC Live Longer
2
Six Years Later, Most Myeloma Patients on a Darzalex Regimen Are Still Progression-Free
3
5 Years of Breast Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
4
10 Cancer Treatment Approvals From September 2026 and What They Mean for You
5